GlaxoSmithKline Plc (GSK) (GSK.L) said on Monday it plans to raise its stake in its Indian pharmaceutical unit to up to 75 percent from 50.7 percent through an open offer in a deal worth about 629 million pounds ($1.02 billion).
With the latest India deal, GSK is set to spend close to $2 billion in roughly a year to increase its holdings in two listed Indian companies, underscoring the British drugmaker's drive to deepen its footprint in emerging markets.